<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657055</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-21-EU</org_study_id>
    <nct_id>NCT04657055</nct_id>
  </id_info>
  <brief_title>AcQBlate Force Sensing Ablation System EU Study for Atrial Flutter (AcQForce Flutter-EU)</brief_title>
  <acronym>AFL-EU</acronym>
  <official_title>AcQBlate Force Sensing Ablation System EU Study for Atrial Flutter (AcQForce Flutter-EU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acutus Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acutus Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Acutus Medical AcQForce Flutter-EU clinical study is a prospective, multi-center,&#xD;
      non-randomized global study designed to confirm the safety and effectiveness of the AcQBlate&#xD;
      Force Sensing Ablation System in the ablation management of symptomatic cavotricuspid isthmus&#xD;
      dependent atrial flutter. The AcQForce Flutter-EU study is a post-market study that will be&#xD;
      run in parallel with a US IDE study of similar design. Data will be combined to support a&#xD;
      pre-market approval (PMA) application to the US Food and Drug Administration (FDA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects free from procedure/device related Serious Adverse Events (SAEs)</measure>
    <time_frame>7 days</time_frame>
    <description>Subjects free from a composite list of pre-specified procedure/device related Serious Adverse Events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects achieving acute procedural success</measure>
    <time_frame>20 minutes post ablation</time_frame>
    <description>Acute procedural success is defined as the demonstration of bidirectional cavotricuspid isthmus block at least 20 minutes following the last radiofrequency application at the cavotricuspid isthmus with the investigational System.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Typical Atrial Flutter</condition>
  <arm_group>
    <arm_group_label>Non-randomized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects with typical atrial flutter will undergo percutaneous catheter ablation of the cavotricuspid isthmus using the AcQBlate Force Sensing System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The AcQBlateÂ® Force Sensing Ablation System</intervention_name>
    <description>Percutaneous catheter ablation of the cavotricuspid isthmus</description>
    <arm_group_label>Non-randomized</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects are clinically indicated for de novo catheter ablation of typical atrial&#xD;
             flutter.&#xD;
&#xD;
          2. At least one (1) documented episode of typical atrial flutter within 180 days (6&#xD;
             months) prior to enrollment, documented by 12-lead ECG.&#xD;
&#xD;
          3. Age 18 years or older at time of consent.&#xD;
&#xD;
          4. Subjects are willing and able to provide written informed consent to participate in&#xD;
             the study and agree to comply with all follow-up visits and evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In the opinion of the Investigator, any contraindication to the planned atrial&#xD;
             ablation, including contraindications to anticoagulation therapy and any other&#xD;
             significant uncontrolled or unstable medical condition (e.g. sepsis, acute metabolic&#xD;
             illness, chronic kidney disease).&#xD;
&#xD;
          2. Inability to entrain CTI dependent AFL by standard pacing at procedure.&#xD;
&#xD;
          3. Any prior right atrial cavotricuspid isthmus ablation.&#xD;
&#xD;
          4. Any cardiac ablation for non-atrial flutter arrhythmias within 90 days prior to&#xD;
             enrollment.&#xD;
&#xD;
          5. Any patient scheduled or anticipating an AF ablation within the follow-up period.&#xD;
&#xD;
          6. Use of amiodarone within 120 days prior to procedure.&#xD;
&#xD;
          7. Cardiac surgery within 60 days prior to enrollment.&#xD;
&#xD;
          8. ST-elevation myocardial infarction (STEMI) within 60 days prior to enrollment&#xD;
&#xD;
          9. Current unstable angina.&#xD;
&#xD;
         10. Documented atrial or ventricular tumors, clots, thrombus, within 30-days prior to&#xD;
             enrollment.&#xD;
&#xD;
         11. Any history of a known hematologic disorder (bleeding/clotting).&#xD;
&#xD;
         12. Implantation of permanent leads of an implantable device in or through the right&#xD;
             atrium within 90-days prior to enrollment.&#xD;
&#xD;
         13. Subjects with New York Heart Association (NYHA) Class IV heart failure within 6-months&#xD;
             prior to enrollment.&#xD;
&#xD;
         14. Subjects with an ejection fraction less than 30% within 90 days of enrollment.&#xD;
&#xD;
         15. Percutaneous Transluminal Coronary Angioplasty (PTCA) within 30-days of enrollment.&#xD;
&#xD;
         16. Clinically significant structural heart disease (including moderate to severe&#xD;
             tricuspid valve regurgitation, tricuspid valve stenosis, or tricuspid valve&#xD;
             replacement; Ebstein's anomaly, or other congenital heart disease) that would preclude&#xD;
             catheter introduction and placement, as determined by the Investigator.&#xD;
&#xD;
         17. Any cerebral ischemic/infarct event (excluding transient ischemic attacks) within 180&#xD;
             days prior to enrollment.&#xD;
&#xD;
         18. Body Mass Index (BMI) &gt;42 kg/m2.&#xD;
&#xD;
         19. International Normalized Ratio (INR) &gt; 3.&#xD;
&#xD;
         20. Severe uncontrolled systemic hypertension (systolic pressure &gt; 240 mm Hg) within the&#xD;
             last 30-days.&#xD;
&#xD;
         21. Women who are pregnant or plan to become pregnant within the course of their&#xD;
             participation in the investigation.&#xD;
&#xD;
         22. Current enrollment in any other study protocol where testing or results from the study&#xD;
             may interfere with the procedure or outcome measurements for this study.&#xD;
&#xD;
         23. Any other condition that, in the judgment of the Investigator, makes the patient a&#xD;
             poor candidate for this procedure, the study or compliance with the protocol (includes&#xD;
             vulnerable patient population, mental illness, addictive disease, terminal illness&#xD;
             with a life expectancy of less than two years, extensive travel away from the research&#xD;
             center).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Daubert, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jerald Cox, PA</last_name>
    <phone>762-529-6310</phone>
    <email>jerry.cox@acutus.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victoria Low, BS</last_name>
    <phone>858-472-6577</phone>
    <email>victoria.low@acutus.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Schwagten, MD</last_name>
      <email>bruno.schwagten@zna.be</email>
    </contact>
    <contact_backup>
      <last_name>Tanja Van Den Stock, RN</last_name>
      <email>tanja.vandenstock@zna.be</email>
    </contact_backup>
    <investigator>
      <last_name>Bruno Schwagten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Vijgen, MD</last_name>
      <phone>+32 11 33 70 31</phone>
      <email>Johan.vijgen@jessazh.be</email>
    </contact>
    <contact_backup>
      <last_name>Arne Janssen</last_name>
      <phone>+32 11 33 70 31</phone>
      <email>Arne.Janssen@jessazh.be</email>
    </contact_backup>
    <investigator>
      <last_name>Johan Vijgen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon James, MD</last_name>
      <email>simon.james1@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Deborah Athorne, RN</last_name>
      <phone>+01642 282410</phone>
      <email>deborah.athorne@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Simon James, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial flutter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

